Lorenzo Galluzzi Selected Research

Toll-Like Receptor Agonists

1/2018	Trial Watch: Toll-like receptor agonists in cancer immunotherapy.
1/2017	Trial watch: Dendritic cell-based anticancer immunotherapy.
3/2016	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.
1/2014	Trial Watch: Toll-like receptor agonists in oncological indications.
9/2013	Trial Watch: Anticancer radioimmunotherapy.
8/2013	Trial Watch: Toll-like receptor agonists for cancer therapy.
9/2012	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
8/2012	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lorenzo Galluzzi Research Topics

Disease

212	Neoplasms (Cancer) 04/2022 - 01/2007
18	Carcinoma (Carcinomatosis) 01/2022 - 07/2008
18	Carcinogenesis 01/2021 - 01/2011
16	Breast Neoplasms (Breast Cancer) 01/2021 - 05/2012
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2019 - 07/2007
12	Melanoma (Melanoma, Malignant) 12/2021 - 01/2014
12	Necrosis 01/2017 - 02/2009
9	Disease Progression 01/2022 - 05/2012
9	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 02/2008
8	Tetraploidy 05/2013 - 12/2007
7	Inflammation (Inflammations) 01/2022 - 05/2009
5	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 05/2012
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 02/2008
4	Obesity 01/2021 - 09/2013
4	Genomic Instability 01/2021 - 07/2010
4	Bites and Stings (Sting) 10/2020 - 01/2018
4	Leukemia 01/2020 - 11/2012
4	Infections 01/2020 - 06/2011
4	Starvation 10/2019 - 06/2008
3	Ovarian Epithelial Carcinoma 01/2022 - 01/2022
3	Triple Negative Breast Neoplasms 01/2021 - 10/2020
3	Hypoxia (Hypoxemia) 01/2021 - 06/2008
3	Lung Neoplasms (Lung Cancer) 01/2019 - 08/2012
3	Prostatic Neoplasms (Prostate Cancer) 10/2013 - 10/2012
2	Squamous Cell Carcinoma of Head and Neck 01/2022 - 01/2020
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2021
2	Reperfusion Injury 01/2021 - 09/2013
2	Condylomata Acuminata (Genital Wart) 01/2020 - 09/2012
2	Actinic Keratosis 01/2020 - 09/2012

Drug/Important Bio-Agent (IBA)

32	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 01/2011
25	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
25	AntigensIBA 01/2020 - 10/2010
23	VaccinesIBA 01/2022 - 03/2012
18	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2008
16	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 11/2007
11	Monoclonal AntibodiesIBA 01/2021 - 01/2012
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
10	CalreticulinIBA 01/2021 - 12/2009
10	CytokinesIBA 01/2021 - 07/2012
10	Adenosine Triphosphate (ATP)IBA 01/2021 - 06/2008
10	Cisplatin (Platino)FDA LinkGeneric 10/2014 - 12/2007
9	Phosphotransferases (Kinase)IBA 01/2017 - 07/2008
8	AnthracyclinesIBA 01/2021 - 10/2010
8	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 03/2012
8	Peptides (Polypeptides)IBA 01/2021 - 12/2012
8	Therapeutic UsesIBA 01/2021 - 08/2012
8	Toll-Like Receptor AgonistsIBA 01/2018 - 08/2012
6	Pattern Recognition ReceptorsIBA 01/2022 - 02/2010
6	LigandsIBA 10/2020 - 10/2010
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2013 - 07/2007
5	Hormones (Hormone)IBA 01/2021 - 10/2012
5	Cytostatic AgentsIBA 01/2021 - 12/2015
5	Imiquimod (Aldara)FDA LinkGeneric 01/2020 - 08/2012
5	ErbB Receptors (EGF Receptor)IBA 09/2013 - 07/2007
4	EpitopesIBA 01/2022 - 01/2018
4	PlatinumIBA 01/2022 - 01/2020
4	CarcinogensIBA 01/2021 - 09/2012
4	Phenobarbital (Luminal)FDA Link 01/2021 - 01/2020
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2020 - 03/2012
4	Interferon Type IIBA 10/2020 - 01/2019
4	InterleukinsIBA 01/2020 - 03/2010
4	Pharmaceutical PreparationsIBA 11/2019 - 01/2014
4	EnzymesIBA 01/2019 - 12/2011
4	Biological ProductsIBA 01/2019 - 07/2012
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2014 - 03/2012
3	InterferonsIBA 01/2022 - 01/2020
3	Chimeric Antigen ReceptorsIBA 01/2021 - 11/2015
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 03/2011
3	Cyclin-Dependent Kinase 4IBA 01/2021 - 11/2020
3	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020 - 08/2012
3	HMGB1 Protein (HMG1)IBA 01/2019 - 03/2012
3	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2017
3	Formaldehyde (Formol)FDA Link 01/2018 - 08/2012
3	Protein Subunit VaccinesIBA 04/2015 - 12/2012
3	Vitamin B 6IBA 10/2014 - 08/2012
3	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2014 - 03/2012
3	Gefitinib (Iressa)FDA Link 09/2013 - 12/2008
3	Digoxin (Digitek)FDA LinkGeneric 02/2013 - 07/2012
3	Cytotoxins (Cytolysins)IBA 08/2012 - 10/2010
3	Sirolimus (Rapamycin)FDA Link 01/2012 - 06/2008
2	S-1,2-dichlorovinyl-N-acetylcysteineIBA 01/2022 - 01/2021
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2022 - 01/2020
2	palbociclibIBA 01/2021 - 11/2020
2	CarbohydratesIBA 01/2021 - 01/2018
2	Serine (L-Serine)FDA Link 01/2021 - 01/2021
2	ChromatinIBA 01/2021 - 01/2013
2	Death Domain ReceptorsIBA 01/2021 - 10/2010
2	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2021 - 01/2020
2	Cell Cycle ProteinsIBA 11/2020 - 01/2020
2	AntibodiesIBA 10/2020 - 01/2012
2	Mitochondrial DNA (mtDNA)IBA 10/2020 - 01/2005
2	theasinensin AIBA 01/2020 - 01/2019
2	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2020 - 08/2012
2	Bortezomib (Velcade)FDA Link 01/2020 - 04/2015
2	Diazepam Binding InhibitorIBA 12/2019 - 10/2019

Therapy/Procedure

89	Therapeutics 01/2022 - 07/2008
36	Immunotherapy 01/2021 - 09/2012
30	Drug Therapy (Chemotherapy) 01/2022 - 01/2007
28	Radiotherapy 04/2022 - 12/2007
3	Oncolytic Virotherapy 02/2016 - 06/2013